Delix Therapeutics closes $100 million Series C financing to advance Zalsupindole into Phase II development. The round was led by strategic pharma and SV Health neurodegen fund.
Amount Raised
$100 Million
Round Type
Series C
BostonBiotechnologyData And AnalyticsHealth CareScience And EngineeringInvestors
Description
Delix Therapeutics has successfully closed an oversubscribed Series C financing, raising $100 million. This funding will facilitate the advancement of Zalsupindole into Phase II development and support broader pipeline advancement. The round was led by strategic pharma partners alongside SV Health neurodegeneration fund. This marks a significant milestone for the company's innovative approach to neuroplasticity.
Quick answer
Delix Therapeutics raised $100 Million in a Series C round, dated November 9, 2026. Investors: Strategic Pharma and SV Health neurodegen fund. Delix Therapeutics is based in Boston, Massachusetts, United States.
- How much did Delix Therapeutics raise?
- Delix Therapeutics raised $100 Million in a Series C round on November 9, 2026.
- Who invested in Delix Therapeutics?
- Strategic Pharma and SV Health neurodegen fund are named as investors in this round.
- What does Delix Therapeutics do?
- Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics.
- Where is Delix Therapeutics based and how big is it?
- Delix Therapeutics is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Delix Therapeutics?
- Fundz holds 1 contact at Delix Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Data And Analytics and Science And Engineering around the same time
Companies in the same sectors as Delix Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Specific Biologics raised $35M (Series A) on November 2, 2026.
- MedinCell raised $15M (Debt Financing) on October 13, 2026.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
Who to call at Delix Therapeutics, and when
A new round usually means Delix Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Delix Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Delix Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Delix Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Delix Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Delix Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.